Skip to main content

Preoperative Labs

In the contemporary preoperative-testing literature, routine "screening" labs in healthy ASA 1–2 patients undergoing low-risk procedures are low-value, drive false-positive workups, and delay care without changing outcomes.[1] This page is the labs-themselves companion to the broader Preoperative Assessment workflow.

When NOT to Order​

Routine CBC, metabolic and coagulation panels are often unnecessary for a healthy patient having a minor procedure. Operation magnitude, comorbidities, medication use, prior results and anticipated blood loss determine testing. NICE NG45 recommends a CBC for major or complex surgery even in ASA 1–2 patients, while discouraging routine coagulation testing without an indication.[9] The NICE adult framework leaves pediatric hypospadias surgery outside its scope.[1][9]

Samsel 2025 retrospectively reviewed 634 urogynecologic surgeries and found that 74% of women had preoperative labs performed, but clinically meaningful lab abnormalities were rare and did not change surgical management in any case. This single-center observational study supports selective testing.[4]

Section 1 — Complete Blood Count (CBC)​

Indicated when:

  • Major reconstructive procedures. Obtain a CBC early when significant blood loss is anticipated, for example radical cystectomy with urinary diversion, complex multistage urethroplasty with flap, abdominal sacrocolpopexy, gracilis-flap reconstruction for rectourethral fistula, or vesicovaginal fistula repair after radiation. If anemia is found, investigate its cause; assess iron deficiency with ferritin and, when inflammation complicates interpretation, transferrin saturation.[11]
  • Patients on testosterone replacement therapy (TRT). Monitor for erythrocytosis. AUA advises considering withholding initiation when baseline Hct is >50% pending evaluation; on-treatment Hct ≥54% requires intervention, commonly dose adjustment and investigation. Follow the TRT monitoring plan; not every formulation is stopped automatically[2]
  • Chronic hematuria. Quantify anemia before reconstruction
  • Recent chemotherapy or known cytopenias. Assess current blood counts and treatment recovery before a planned major operation
  • Known myelodysplasia, hemoglobinopathy, or chronic kidney disease

Usually omit a new CBC: low-blood-loss minor procedures in patients without an anemia or bleeding indication and with an appropriate recent assessment. Consider procedure magnitude and local anesthesia policy.[9]

Section 2 — Coagulation Studies (PT/INR, aPTT)​

Indicated when:

  • Personal or family history suggesting a bleeding disorder
  • Warfarin. INR is checked when needed for the perioperative plan. Routine PT/aPTT cannot reliably exclude DOAC effect; when residual drug activity would change urgent management, use a drug-appropriate assay and expert interpretation
  • Liver disease or a suspected acquired coagulation defect, including clinically relevant vitamin K deficiency
  • Unfractionated heparin when monitoring is needed; LMWH exposure does not by itself justify routine PT/aPTT
  • Severe systemic illness or sepsis

Skip when: Healthy ASA 1–2 patients with no bleeding history. Published perioperative guidance discourages reflex PT/aPTT before noncardiac surgery in unselected patients.[1]

For perioperative anticoagulation timing and reversal strategy, see Antithrombotic Therapy and Anticoagulation Reversal.

Section 3 — Glucose / HbA1c​

HbA1c reflects preceding glycemia rather than an acute stress response, but altered red-cell survival, transfusion and some hemoglobin variants can make it misleading. Interpret it alongside current glucose and the clinical setting.[3]

Indicated when:

  • Known diabetes: confirm current control before elective major reconstruction
  • Diabetes case-finding when indicated by standard risk-based assessment or unexplained hyperglycemia; do not add HbA1c to every preoperative panel solely because surgery is planned
  • Refractory recurrent UTI, voiding dysfunction, or NLUTD presentations where occult diabetes is on the differential

Targets and timing. ADA 2026 recommends aiming for HbA1c <8% within 3 months before elective surgery with individualized risk–benefit assessment (grade C).[5] With 14-day CGM data, glucose management indicator <8% or time in range >50% may also be used (grade E).[5] It explicitly advises against postponing surgery on A1c or glucose-management indicator alone, because evidence that such delay improves outcomes is lacking. AHA/ACC 2024 considers a preoperative HbA1c reasonable (Class 2a) in people with or at risk for diabetes when none has been measured in the past 3 months. AHA/ACC 2024 says postponing elective surgery may be reasonable when HbA1c exceeds 8%, while noting no evidence that deferral improves cardiovascular outcomes; for adults with diabetes undergoing elective surgery, the Endocrine Society suggests HbA1c <8% and glucose 100–180 mg/dL, with glucose in that range 1–4 hours before surgery (weak recommendations; very low certainty).[5][6][7]

Glycosuria should be interpreted with plasma glucose, medications and renal physiology. It is expected during SGLT2-inhibitor use and does not by itself diagnose diabetes or poor control.

SGLT2 inhibitor caveat. SGLT2 inhibitors (canagliflozin, dapagliflozin, empagliflozin, ertugliflozin) should be withheld 3 days before elective surgery (4 days for ertugliflozin) to reduce the risk of perioperative euglycemic diabetic ketoacidosis.[6]

Skip when: ASA 1–2 patients with no diabetes risk factors undergoing low-risk procedures.

For broader diabetes optimization (insulin holds, SGLT2 inhibitor euglycemic DKA risk, perioperative insulin and glucose monitoring), see the Preoperative Assessment — Diabetes page.

Section 4 — BMP / CMP​

For routine general preoperative use (distinct from the lifelong diversion-specific surveillance covered at Renal Function & Metabolic Surveillance):

Indicated when:

  • Chronic kidney disease. Review recent creatinine and electrolytes; obtain new results when the procedure, AKI risk, or medication and fluid plan makes them relevant.[9]
  • On diuretics, ACE inhibitors, or ARBs: risk for hypokalemia, hyperkalemia, or pre-renal AKI
  • On medications with renal clearance (gabapentin, vancomycin, LMWH, methotrexate) requiring dose adjustment
  • Major surgery with anticipated significant fluid shifts (cystectomy, large flap reconstruction, prolonged operative time)
  • Adrenal insufficiency or chronic corticosteroid use (electrolyte and glucose baseline)

Skip when: Healthy ASA 1–2 patients undergoing outpatient or short-stay procedures, no medications requiring renal monitoring.[1]

Section 5 — Type and Screen / Type and Crossmatch​

Match the order to anticipated blood-loss volume:

  • Type and screen: radical cystectomy with urinary diversion, complex urethroplasty with flap, large pedicled or free flap reconstruction (gracilis, VRAM, ALT), open sacrocolpopexy, complex fistula repair after radiation, augmentation cystoplasty, posterior urethroplasty for PFUI
  • Crossmatch / reserve units: when the expected transfusion requirement and local blood-ordering schedule justify it. Known antibodies warrant early blood-bank coordination
  • Skip: outpatient endoscopic procedures, simple slings, office-based procedures

Institutional MSBOS (maximum surgical blood ordering schedule) policies operationalize this. Confirm local conventions.

When to Order vs. Skip — Quick Reference​

LabOrder WhenSkip When
CBCMajor reconstruction; chronic hematuria; on TRT; post-chemotherapy cystectomyCystoscopy; simple sling; minor low-blood-loss procedures without an anemia indication
PT/INR/aPTTBleeding history, warfarin monitoring or suspected coagulation defect; select the assay for the drugHealthy ASA 1–2 with no bleeding history
BMP/CMPCKD; on diuretics/ACE-I/ARB; major fluid shifts; chronic steroidsRoutine outpatient procedures in ASA 1–2
HbA1cKnown DM without a recent result; indicated diabetes case-findingASA 1–2 with no diabetes risk factors
Type & ScreenCystectomy/diversion; complex urethroplasty; large flap; open sacrocolpopexy, guided by anticipated blood loss and local MSBOSOutpatient endoscopic procedures
Type & CrossmatchExpected transfusion need and local blood-bank planRoutine cases without bleeding-risk features

Reconstruction-Specific Risk Factors That Change the Calculus​

  • Long-standing urinary diversion. Ileal and colonic segments can cause hyperchloremic metabolic acidosis; electrolyte disturbances, including potassium changes, depend on segment and renal function. B12 deficiency risk increases with longer ileal resection. See Renal Function & Metabolic Surveillance.[10]
  • Spinal cord injury or NLUTD. In unknown-, moderate-, or high-risk NLUTD, review renal function; in spinal cord injury, a creatinine rise from baseline may matter even within the normal range, and cystatin C can help when muscle mass is low. Plan for autonomic dysreflexia during lower urinary tract instrumentation.[13]
  • Radiation history. Anemia from chronic radiation cystitis bleeding, marrow effects from prior pelvic radiation
  • Patients receiving testosterone, including gender-affirming testosterone. Hematocrit is monitored during treatment under the guideline applicable to the indication.[2][12]
  • Geriatric reconstructive patients. Assess frailty, function, comorbidities and nutritional intake, then select labs. Albumin is influenced by inflammation and illness.
  • Diabetes before urinary diversion. In Kim's observational cohort of 123 ileal-neobladder patients, diabetes was associated with acidosis at one year (adjusted OR 5.68). See Renal Function & Metabolic Surveillance for the lifelong post-diversion lab framework.[8]

See Also​

References​

1. Feely MA, Collins CS, Daniels PR, Kebede EB, Jatoi A, Mauck KF. "Preoperative Testing Before Noncardiac Surgery: Guidelines and Recommendations." Am Fam Physician. 2013;87(6):414–418. https://www.aafp.org/pubs/afp/issues/2013/0315/p414.html

2. AUA. Evaluation and Management of Testosterone Deficiency (2018; validity confirmed 2024). Guideline.

3. Sacks DB, Arnold M, Bakris GL, et al. "Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus." Diabetes Care. 2023;46(10):e151–e199. doi:10.2337/dci23-0036

4. Samsel T, Ashmore S, Shi J, Kenton K, Mueller M. "Surgical Management of Pelvic Floor Disorders and the Utility of Preoperative Labs." Int Urogynecol J. 2025. doi:10.1007/s00192-025-06307-7

5. American Diabetes Association Professional Practice Committee. "16. Diabetes Care in the Hospital: Standards of Care in Diabetes—2026." Diabetes Care. 2026;49(Suppl_1):S339–S355. doi:10.2337/dc26-S016

6. Thompson A, Fleischmann KE, Smilowitz NR, et al. "2024 AHA/ACC/ACS/ASNC/HRS/SCA/SCCT/SCMR/SVM Guideline for Perioperative Cardiovascular Management for Noncardiac Surgery." J Am Coll Cardiol. 2024;84(19):1869–1969. doi:10.1016/j.jacc.2024.06.013

7. Korytkowski MT, Muniyappa R, Antinori-Lent K, et al. "Management of Hyperglycemia in Hospitalized Adult Patients in Non-Critical Care Settings: An Endocrine Society Clinical Practice Guideline." J Clin Endocrinol Metab. 2022;107(8):2101–2128. doi:10.1210/clinem/dgac278

8. Kim KH, Yoon HS, Yoon H, et al. "Risk Factors for Developing Metabolic Acidosis after Radical Cystectomy and Ileal Neobladder." PLoS One. 2016;11(7):e0158220. doi:10.1371/journal.pone.0158220

9. NICE. Routine preoperative tests for elective surgery, NG45. Recommendations by surgery and ASA grade.

10. Stein R, Rubenwolf P. "Metabolic consequences after urinary diversion." Front Pediatr. 2014;2:15. doi:10.3389/fped.2014.00015

11. Hands K, Daru J, Evans C, et al. "Identification and management of preoperative anaemia in adults: A British Society for Haematology Guideline update." Br J Haematol. 2024;205(1):88–99. doi:10.1111/bjh.19440

12. Hembree WC, Cohen-Kettenis PT, Gooren L, et al. "Endocrine treatment of gender-dysphoric/gender-incongruent persons: An Endocrine Society clinical practice guideline." J Clin Endocrinol Metab. 2017;102(11):3869–3903. doi:10.1210/jc.2017-01658

13. Ginsberg DA, Boone TB, Cameron AP, et al. "The AUA/SUFU Guideline on Adult Neurogenic Lower Urinary Tract Dysfunction: Diagnosis and Evaluation." J Urol. 2021;206(5):1097–1105. doi:10.1097/JU.0000000000002235